BCEIE › News › INDOBORAX

M&A

Indo Borax & Chemicals: Completion of the acquisition of 64.26% of the share capital of Kronox Lab Sciences Limited

Indo Borax & Chemicals (INDOBORAX) filed a disclosure titled "Completion of the acquisition of 64.26% of the share capital of Kronox Lab Sciences Limited". The company is valued at about ₹1,525 crore.

BCEIE News Desk · Published 29 Sept 2026, 04:01 pm IST · Filing received 29 Sept 2026, 03:44 pm IST

What happened

Indo Borax & Chemicals (INDOBORAX) filed a disclosure with the exchanges on 29 September 2026 at 03:44 PM titled "Completion of the acquisition of 64.26% of the share capital of Kronox Lab Sciences Limited".

Company snapshot

Indo Borax & Chemicals is a small-cap company, with a market value of about ₹1,525 crore.

The stock last traded at ₹475.4, against a 52-week range of ₹230–₹542.8 (12.4% below the high).

Before this filing the shares had moved −4.0% over the month and +26.3% over three months. Average daily turnover over the last 20 sessions was about ₹24.81 crore.

Promoters held 38.41% at the end of Q1 FY27, up 7.61% points from the previous quarter; 100.00% of promoter shares were pledged. Foreign institutions owned 0.13% and domestic institutions 0.04%.

Quarterly results (consolidated, ₹ crore)
QuarterRevenueNet profitEPS (₹)
Q1 FY26541.13.18
Q2 FY2611128.78.25
Q3 FY26419.92.89
Q4 FY266315.84.53
Q1 FY277016.35.07

What history shows

This is not the company's first m&a disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.

After those filings, the stock gained 0.2% on average the next trading day and was down 0.9% on average after five days (2 filings with price data).

Market-wide, 1,921 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 50% rising.

Past reactions describe what happened before; they are not a forecast.

Earlier filings of this kind
DateFilingNext day5 days
20 Aug 2026M&A+18.0%+15.9%
21 Jul 2026Amalgamation/Merger−17.5%−17.8%

What to watch

  • Regulatory approvals, completion of the deal and its effect on revenue and margins.

In the news

Recent coverage elsewhere (links open the original publisher):

Source

Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.